Continuous subcutaneous infusion of apomorphine for the treatment of Parkinson's disease;L'apomorphine en perfusion sous-cutanée continue dans le traitement de la maladie de Parkinson

Revue Neurologique

Volumn 162, Issue 10, 2006, Pages 1019-1023

  Drapier, S ^a   Vérin, Marc ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Apomorphine Pump; Continuous Subcutaneous Infusion; Parkinson Disease

Indexed keywords

APOMORPHINE;

CLINICAL TRIAL; CONFERENCE PAPER; CONFUSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; HALLUCINATION; HUMAN; MEDICAL LITERATURE; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; SEDATION; SIDE EFFECT; SOMNOLENCE; VOMITING;

EID: 33749350241     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(06)75115-3     Document Type: Conference Paper

References (33)

1. ACLAND KM, LESLIE T, DOWD PM. (1998). Panniculitis associated with subcutaneous apomorphine. Hosp Med, 59: 413-414.
2. ALEGRET M, VALLDEORIOLA F, MARTI M, PILLERI M, JUNQUE C, RUMIA J, TOLOSA E. (2004). Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease. Mov Disord, 19: 1463-1469.
3. ANDERSON VC, BURCHIEL KJ, HOGARTH P, FAVRE J, HAMMERSTAD JP. (2005). Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. Arch Neurol, 62: 554-560.
4. COLOSIMO C, MERELLO M, ALBANESE A. (1994). Clinical usefulness of apomorphine in movement disorders. Clin Neuropharmacol, 17: 243-259.
5. COLZI A, TURNER K, LEES AJ. (1998). Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry, 64: 573-576.
6. CORBOY DL, WAGNER ML, SAGE JI. (1995). Apomorphine for motor fluctuations and freezing in Parkinson's disease. Ann Pharmacother, 29: 282-288.
7. CORSINI GU, DEL ZOMPO M, GESSA GL, MANGONI A. (1979). Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease. Lancet, 1: 954-956.
8. DEWEY RB, HUTTON JT, LEWITT PA, FACTOR SA. (2001). A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol, 58: 1385-1392.
9. ELLIS C, LEMMENS G, PARKES D, ABBOTT RJ, PYE IF, NIGEL LEIGH P, CHAUDHURI KR. (1997). Use of Apomorphine in Parkinsonian Patients with Neuropsychiatrie Complications to Oral Treatment. Parkinsonism Relat Disord, 3: 103-107.
10. FRANKEL JP, LEES AJ, KEMPSTER PA, STERN GM. (1990). Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry, 53: 96-101.
11. FUNKIEWIEZ A, ARDOUIN C, CAPUTO E et al. (2004). Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry, 75: 834-839.
12. GANCHER ST, WOODWARD WR, BOUCHER B, NUTT JG. (1989). Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol, 26: 232-238.
13. HAGELL P, ODIN P. (2001). Apomorphine in the treatment of Parkinson's disease. J Neurosci Nurs, 33: 21-34, 37-28.
14. HUGHES AJ, BISHOP S, KLEEDOREER B, TURJANSKI N, FERNANDEZ W, LEES AJ, STERN GM. (1993). Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord, 8: 165-170.
15. JENNER P. (2002). Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology, 58: S1-S8.
16. KANOVSKY P, KUBOVA D, BARES M, HORTOVA H, STREITOVA H, REKTOR I, ZNOJIL V. (2002). Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Mov Disord, 17: 188-191.
17. KEMPSTER PA, FRANKEL JP, STERN GM, LEES AJ. (1990). Comparison of motor response to apomorphine and levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatry, 53: 1004-1007.
18. LEES AJ. (1993). Dopamine agonists in Parkinson's disease: a look at apomorphine. Fundam Clin Pharmacol, 7: 121-128.
19. LEWITT PA. (2004). Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology, 62: S8-S11.
20. MANSON AJ, TURNER K, LEES AJ. (2002). Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord, 17: 1235-1241.
21. MATTHIESSEN A, WRIGHT CRA. (1869). Researches into the chemical constitution of the opium bases. Part I. On the action of hydrochloric acid on morphia. Proc R Soc Lond, 17: 455-460.
22. NEEF C, VAN LAAR T. (1999). Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Clin Pharmacokinet, 37: 257-271.
23. O'SULLIVAN JD, LEES AJ. (1999). Use of apomorphine in Parkinson's disease. Hosp Med, 60: 816-820.
24. PIETZ K, HAGELL P, ODIN P. (1998). Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J Neurol Neurosurg Psychiatry, 65: 709-716.
25. POEWE W, KLEEDORFER B, GERSTENBRAND F, OERTEL W. (1988). Subcutaneous apomorphine in Parkinson's disease. Lancet, 1: 943.
26. POEWE W, WENNING GK. (2000). Apomorphine: an underutilized therapy for Parkinson's disease. Mov Disord, 15: 789-794.
27. POLLAK P, CHAMPAY AS, HOMMEL M, PERRET JE, BENABID AL. (1989). Subcutaneous apomorphine in Parkinson's disease. J Neurol Neurosurg Psychiatry, 52: 544.
28. POLLAK P, GERVASON CL. (1991). [Use of apomorphine in the treatment of Parkinson's disease]. Presse Med, 20: 1361-1364.
29. RODRIGUEZ-OROZ MC, OBESO JA, LANG AE et al. (2005). Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain, 128: 2240-2249.
30. RUZICKA E, ROTH J, SPACKOVA N, MECIR P, JECH R. (1994). Apomorphine induced cognitive changes in Parkinson's disease. J Neurol Neurosurg Psychiatry, 57: 998-1001.
31. SCHWAB RS, AMADOR LV, LETTVIN JY. (1951). Apomorphine in Parkinson's disease. Trans Am Neurol Assoc, 56: 251-253.
32. STEFANI C, DRAPIER S, PERRON J, SAULEAU P, VERIN M. (2005). Continuous subcutaneous apomorphine infusion: an effective and cognitive well-tolerated solution for untreatable motor fluctuations in patients with Parkinsons disease. Presented at American Academy of Neurology, Miami.
33. STIBE CM, LEES AJ, KEMPSTER PA, STERN GM. (1988). Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet, 1: 403-406.